INVALID TRIAL
Both CHIA and your personal trial have the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Age greater than or equal to 18 years              │ Age greater than or equal to 18 years              │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Have RA, as defined by the 1987 revised American   │ Have RA, as defined by the 1987 revised American   │     100 │
│ College of Rheumatology criteria                   │ College of Rheumatology criteria                   │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ In sustained clinical remission for the last 6     │ In sustained clinical remission for the last 6     │     100 │
│ months while receiving treatment with either       │ months while receiving treatment with either       │         │
│ etanercept, infliximab, or adalimumab, and greater │ etanercept, infliximab, or adalimumab, and greater │         │
│ than or equal to 1 DMARD (methotrexate,            │ than or equal to 1 DMARD (methotrexate,            │         │
│ hydroxychloroquine, sulfasalazine, leflunomide,    │ hydroxychloroquine, sulfasalazine, leflunomide,    │         │
│ minocycline, cyclosporine, azathioprine, gold,     │ minocycline, cyclosporine, azathioprine, gold,     │         │
│ penicillamine). DAS28 should be less than 2.6 on   │ penicillamine). DAS28 should be less than 2.6 on   │         │
│ each visit over the preceding 6 months, with at    │ each visit over the preceding 6 months, with at    │         │
│ least one visit 2-4 months before enrollment. If   │ least one visit 2-4 months before enrollment. If   │         │
│ there is no visit 6 months before enrollment, the  │ there is no visit 6 months before enrollment, the  │         │
│ nearest visit in the 6-12 month period before      │ nearest visit in the 6-12 month period before      │         │
│ enrollment should be considered and have a DAS28   │ enrollment should be considered and have a DAS28   │         │
│ less than 2.6                                      │ less than 2.6                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Had dose increase of anti-TNF agent or DMARD in    │ Had dose increase of anti-TNF agent or DMARD in    │     100 │
│ the last 6 months                                  │ the last 6 months                                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Had change of anti-TNF agent or DMARD in the last  │ Had change of anti-TNF agent or DMARD in the last  │     100 │
│ 6 months                                           │ 6 months                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treated currently with golimumab or certolizumab   │ Treated currently with golimumab or certolizumab   │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treated with greater than 10 mg of prednisone (or  │ Treated with greater than 10 mg of prednisone (or  │     100 │
│ equivalent) daily in the last 6 months             │ equivalent) daily in the last 6 months             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treated with greater than 5 mg of prednisone (or   │ Treated with greater than 5 mg of prednisone (or   │     100 │
│ equivalent) daily in the last 3 months             │ equivalent) daily in the last 3 months             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treated with intramuscular or intravenous          │ Treated with intramuscular or intravenous          │     100 │
│ corticosteroids in the last 6 months for RA        │ corticosteroids in the last 6 months for RA        │         │
│ activity                                           │ activity                                           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treated with anakinra, abatacept, or tocilizumab   │ Treated with anakinra, abatacept, or tocilizumab   │     100 │
│ in the last 6 months                               │ in the last 6 months                               │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treated with rituximab in the last 12 months       │ Treated with rituximab in the last 12 months       │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treated with an investigational RA drug in the     │ Treated with an investigational RA drug in the     │     100 │
│ last 6 months                                      │ last 6 months                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Pregnant (or anticipate pregnancy during the study │ Pregnant (or anticipate pregnancy during the study │     100 │
│ period) or lactating women                         │ period) or lactating women                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absence of documentation in the medical record of  │ Absence of documentation in the medical record of  │     100 │
│ clinical remission for the last 6 months           │ clinical remission for the last 6 months           │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unwilling to discontinue anti-TNF agent            │ Unwilling to discontinue anti-TNF agent            │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absence of documentation of negative tuberculin    │ Absence of documentation of negative tuberculin    │     100 │
│ skin test, negative QuantiFERON-TB Gold test, or   │ skin test, negative QuantiFERON-TB Gold test, or   │         │
│ treatment for latent tuberculosis prior to         │ treatment for latent tuberculosis prior to         │         │
│ starting treatment with the anti-TNF agent         │ starting treatment with the anti-TNF agent         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Treatment of solid malignancy or non-melanoma skin │ Treatment of solid malignancy or non-melanoma skin │     100 │
│ cancer within the past 5 years, or any history of  │ cancer within the past 5 years, or any history of  │         │
│ melanoma or hematologic or lymphoproliferative     │ melanoma or hematologic or lymphoproliferative     │         │
│ malignancy                                         │ malignancy                                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absence of documentation of age-appropriate cancer │ Absence of documentation of age-appropriate cancer │     100 │
│ screening at the time of randomization             │ screening at the time of randomization             │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Absence of documentation of negative hepatitis B   │ Absence of documentation of negative hepatitis B   │     100 │
│ serologies, absence of completion of treatment for │ serologies, absence of completion of treatment for │         │
│ chronic hepatitis B, or absence of suppressive     │ chronic hepatitis B, or absence of suppressive     │         │
│ antiviral treatment                                │ antiviral treatment                                │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Unable to provide informed consent                 │ Unable to provide informed consent                 │     100 │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Anticipate not being available or able to comply   │ Anticipate not being available or able to comply   │     100 │
│ with the schedule of study visits                  │ with the schedule of study visits                  │         │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

Only your personal trial has the following criteria:
╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╤═════════╕
│ Personal Criteria                                  │ CHIA Criteria                                      │   Score │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╪═════════╡
│ Potential participants will be excluded if         │ Pregnant (or anticipate pregnancy during the study │      40 │
│                                                    │ period) or lactating women                         │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Study entry is not limited by gender or ethnicity. │ In sustained clinical remission for the last 6     │      40 │
│ Children are excluded because inflammatory         │ months while receiving treatment with either       │         │
│ polyarthritis developing before age 16 is          │ etanercept, infliximab, or adalimumab, and greater │         │
│ considered juvenile idiopathic arthritis and not   │ than or equal to 1 DMARD (methotrexate,            │         │
│ RA. Patients who developed RA while age 17 would   │ hydroxychloroquine, sulfasalazine, leflunomide,    │         │
│ be eligible, but given the time needed to achieve  │ minocycline, cyclosporine, azathioprine, gold,     │         │
│ remission, these patients would in most cases be   │ penicillamine). DAS28 should be less than 2.6 on   │         │
│ 18 or older by the time they would meet other      │ each visit over the preceding 6 months, with at    │         │
│ criteria for study entry                           │ least one visit 2-4 months before enrollment. If   │         │
│                                                    │ there is no visit 6 months before enrollment, the  │         │
│                                                    │ nearest visit in the 6-12 month period before      │         │
│                                                    │ enrollment should be considered and have a DAS28   │         │
│                                                    │ less than 2.6                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Participants will largely be recruited from the    │ In sustained clinical remission for the last 6     │      41 │
│ practices of study investigators. To identify      │ months while receiving treatment with either       │         │
│ potential subjects, investigators may search       │ etanercept, infliximab, or adalimumab, and greater │         │
│ rosters of patients in their practice for patients │ than or equal to 1 DMARD (methotrexate,            │         │
│ who meet the inclusion criteria. The number of     │ hydroxychloroquine, sulfasalazine, leflunomide,    │         │
│ patients screened and reasons for exclusion will   │ minocycline, cyclosporine, azathioprine, gold,     │         │
│ be tabulated at each site. Subjects may also be    │ penicillamine). DAS28 should be less than 2.6 on   │         │
│ recruited by physician referral. Information about │ each visit over the preceding 6 months, with at    │         │
│ the study will be mailed to local rheumatologists  │ least one visit 2-4 months before enrollment. If   │         │
│ and posted on the NIAMS website. We do not         │ there is no visit 6 months before enrollment, the  │         │
│ anticipate self-referral of subjects but eligible  │ nearest visit in the 6-12 month period before      │         │
│ self-referred subjects will not be excluded        │ enrollment should be considered and have a DAS28   │         │
│                                                    │ less than 2.6                                      │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ as outlined below. Clinical information will be    │ Absence of documentation in the medical record of  │      42 │
│ obtained from subjects by interview and from the   │ clinical remission for the last 6 months           │         │
│ medical record                                     │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ At the screening visit, potential participants     │ Anticipate not being available or able to comply   │      43 │
│ will be included if                                │ with the schedule of study visits                  │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ During the course of the study, enrollment of      │ Absence of documentation of negative tuberculin    │      43 │
│ subjects treated with a particular anti-TNF agent  │ skin test, negative QuantiFERON-TB Gold test, or   │         │
│ may be suspended or terminated to permit adequate  │ treatment for latent tuberculosis prior to         │         │
│ representation of patients treated with each of    │ starting treatment with the anti-TNF agent         │         │
│ the 3 anti-TNF medications, due to problems        │                                                    │         │
│ procuring medication, or due to other unforeseen   │                                                    │         │
│ issues                                             │                                                    │         │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┼─────────┤
│ Must have minimum age of 18 Years                  │ Age greater than or equal to 18 years              │      49 │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╧═════════╛

CHIA has no unique criteria

Levenshtein Ratio of Entire trial at once: 75
Average Levenshtein Ratio of individual lines: 85.64285714285714
OverAll Ratio: 80.32142857142857
